PMID- 18593365
OWN - NLM
STAT- MEDLINE
DCOM- 20080821
LR  - 20231213
IS  - 1557-8852 (Electronic)
IS  - 1084-9785 (Linking)
VI  - 23
IP  - 3
DP  - 2008 Jun
TI  - Antitumor effect of lung cancer vaccine with umbilical blood dendritic cells in 
      reconstituted SCID mice.
PG  - 321-31
LID - 10.1089/cbr.2008.0463 [doi]
AB  - Dendritic cells (DCs) are important cells in initiating an immune response. A 
      generation of functional DCs has potential clinical use in treating cancer. 
      However, the source of DCs and patient immunodeficiency with cancer have been 
      hindrances in clinical therapy. We generated DCs from human umbilical cord blood 
      mononuclear cells (UBMCs) with recombinant human granulocyte-macrophage colony 
      stimulating factor, recombinant human interleukin-4, and recombinant human tumor 
      necrosis factor-alpha. The mature DC-A549 lung cancer vaccine (AgL-DC) was 
      prepared through loading A549 lysate, treating with lipopolysaccharide (LPS) and 
      positive selecting with CD83 magnetic beads. AgL-DC can secrete interleukin 
      (IL)-12 and IL-1. Further in vitro analysis showed that AgL-DC notably induced 
      human UBMC lymphocyte proliferation (p < 0.01) by 
      3-(4,5-dimethylthiazol-z-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, 
      increased the cytotoxic T-lymphocyte (CTL) activity of UBMC lymphocytes against 
      A549 cells (p < 0.05, at effector cells:target cells ratios of 50:1 and 100:1) by 
      lactate dehydrogenase (LDH) cytotoxic assay, and improved production of IL-6 and 
      tumor necrosis factor-beta (p < 0.01, p < 0.05) by enzyme-linked immunosorbent 
      assay. Subsequently, the reconstitute immunity model in severe combined 
      immunodeficiencies (SCID) mice has been established using human UBMC 
      transplantation, and similar trends to results of UBMC in vitro experiments have 
      been shown in lymphocyte proliferation, CTL activity, and IL-6 and tumor necrosis 
      factor-beta secretion levels in these models. AgL-DC also significantly (p < 
      0.01) increased the antitumor effect in vivo. The tumor infiltrating immunocytes 
      were positively expressed human CD83 and CD3 molecules, and they were negatively 
      expressed in tumor tissue treated with control. These results have demonstrated 
      that umbilical cord DCs are a useful source of vaccine cells for augmenting 
      CTL-mediated cytotoxicity and have potential usefulness in cellular therapy for 
      human cancer in a new vaccination strategy.
FAU - Lin, Ping
AU  - Lin P
AD  - Division of Experimental Oncology, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, People's Republic of China.
FAU - Lu, Yan-Rong
AU  - Lu YR
FAU - Zhang, Jie
AU  - Zhang J
FAU - Wei, Yu-Quan
AU  - Wei YQ
FAU - Wang, Xiu-Jie
AU  - Wang XJ
FAU - Li, Sheng-Fu
AU  - Li SF
FAU - Wang, Qi
AU  - Wang Q
FAU - Xiong, Zhu-Juan
AU  - Xiong ZJ
FAU - Ning, Qi-Zhi
AU  - Ning QZ
FAU - Lei, Song
AU  - Lei S
FAU - Mao, Yong-Qiu
AU  - Mao YQ
FAU - Cheng, Jing-Qiu
AU  - Cheng JQ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (Antigens, CD)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CD3 Complex)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interleukin-6)
RN  - 0 (Lymphotoxin-alpha)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Animals
MH  - Antigens, CD/biosynthesis
MH  - Antineoplastic Agents/pharmacology
MH  - CD3 Complex/biosynthesis
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Dendritic Cells/*cytology
MH  - Humans
MH  - Immune System
MH  - Immunoglobulins/biosynthesis
MH  - Interleukin-6/metabolism
MH  - Lung Neoplasms/*therapy
MH  - Lymphocyte Activation
MH  - Lymphocytes/cytology
MH  - Lymphotoxin-alpha/metabolism
MH  - Membrane Glycoproteins/biosynthesis
MH  - Mice
MH  - Mice, SCID
MH  - Umbilical Veins/*cytology
MH  - CD83 Antigen
EDAT- 2008/07/03 09:00
MHDA- 2008/08/22 09:00
CRDT- 2008/07/03 09:00
PHST- 2008/07/03 09:00 [pubmed]
PHST- 2008/08/22 09:00 [medline]
PHST- 2008/07/03 09:00 [entrez]
AID - 10.1089/cbr.2008.0463 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2008 Jun;23(3):321-31. doi: 10.1089/cbr.2008.0463.